The use of models incorporating ALS-linked mutations such as C9orf72 and TDP-43, as well as corrected variants through CRISPR-Cas9, further emphasizes their potential for advancing precision medicine in ALS (Guo et al., 2024; Nie et al., 2025; Casiraghi et al., 2025; De Majo et al., 2023; Meijboom et al., 2022). The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.